Objective: The aim of this work was to study the microscopic patterns of human immunodeficiency virus (HIV) lymphadenitis on fine-needle aspiration cytology (FNAC) and correlate them with cluster of differentiation 4 (CD4) counts. Study Design: A retrospective study of known HIV-positive patients who underwent lymph node FNAC over a period of 5 years (2009-2013) was undertaken. The cytology slides were retrieved and reviewed. Out of 317 cases, 38 (11.7%) were diagnosed as HIV lymphadenitis. We analysed the cytomorphological patterns of HIV lymphadenitis and correlated them with the CD4 cell counts. Results: Smears of HIV lymphadenitis were classified akin to histology patterns (A, B, and C) depending on cellularity, number of tingible body macrophages, mitosis, apoptotic bodies, plasma cells, Warthin-Finkeldey giant cells, and proliferating blood vessels. Thirty-one cases showed pattern A, 3 showed pattern B, and 4 were of pattern C. Pattern A had the highest CD4 cell count. Conclusion: Histologic patterns of HIV lymphadenitis are recognisable on FNAC smears. These can offer a clue to the diagnosis and guide further workup, even in the absence of history. The changes can mimic those of the infective lymphadenitis, Castleman disease, and lymphoma. Hence, the clinical history, serological correlation, and awareness of cytomorphology can aid the correct diagnosis.

1.
Gujral S, Gandhi JS, Valsangkar S, Shet TM, Epari S, Subramanian PG: Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy. Indian J Pathol Microbiol 2010;53:723-728.
2.
Ioachim HL, Medeiros LJ: Ioachim's lymph node pathology; in Ioachim HL, Medeiros LJ (eds): Human Immunodeficiency Virus Lymphadenitis, ed 4. Philadelphia, Lippincott Williams and Wilkins, 2009, pp 99-105.
3.
Klatzmann D, Barré-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, et al: Selective tropism of lymphadenopathy associated virus (LAV) for help inducer T lymphocytes. Science 1984;225:59-64.
4.
Fox CH, Tenner-Racz K, Racz P, et al: Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 1991;164:1051-1057.
5.
Paiva DD, Morais JC, Pilotto J, Veloso V, Duarte F, Lenzi HL: Spectrum of morphologic changes of lymph nodes in HIV infection. Mem Inst Oswaldo Cruz 1996;91:371-379.
6.
Wenig BM, Thompson LDR, Frankel SS, et al: Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immuno-deficiency virus infection: a clinicopathologic study of 12 cases. Am J Surg Pathol 1996;20:572-587.
7.
Ioachim HL: Pathology of AIDS. Philadelphia, JB Lippincott, 1989.
8.
Jayaram G, Chew MT: Fine needle aspiration cytology of lymph nodes in HIV-infected individuals. Acta Cytol 2000;44:960-966.
9.
Kumarguru BN, Kulkarni MH, Kameken NS: FNAC of peripheral lymphnodes in HIV positive patients. Sci Med 2009;1:4-12.
10.
Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-335.
11.
Ioachim HL, Cronin W, Roy M, Maya M: Persistent lymphadenopathies in people at high risk for HIV infection. Am J Clin Pathol 1990;93:208-218.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.